| 80sM |
Stage IVA, T4NXM0B2 |
CD4:CD8 of 101, discrete subset of CD3+/CD4+/CD26- :61 % (6146 cells/μl) |
4.19% |
Dexamethasone suppression |
| 70sM |
Stage IVA, T4N0M0B2 |
CD4:CD8 of 31.3, discrete subset of CD3+/CD4+/CD26-: 87% (9369 cells/μl) |
6.32% |
Dexa/Vorinostat suppression |
| 60sM |
Stage IVA2 T4N3M0B2 |
CD4:CD8 of 4.9, discrete subset of CD3+/CD4+/CD26-: 41 % (1020 cells/μl) |
12% |
Vorinostat suppression |
| 50sM |
Stage IIIB T4NXM0B1 |
CD4:CD8 of 4.1, discrete subset of CD3+/CD4+/CD26-23% (435 cells/μl) |
2.67% |
Dexamethasone suppression |
| 70sF |
Stage IVA, T2NXM0B2 |
CD4:CD8 of 64.2, discrete subset of CD3+/CD4+/CD26-64% (5833 cells/μl) |
3.34% |
Vorinostat suppression |
| 20sM |
Stage IIIB T4N2M0B1 |
CD4:CD8 of 4.9, discrete subset of CD3+/CD4+/CD26-30% (164 cells/μl) |
1.03% |
Dexa/Vorinostat suppression |
| 60sM |
Stage IVA, T2NXM0B2 |
CD4:CD8 of 22, discrete subset of CD3+/CD4+/CD26-80% (843 cells/μl) |
4.73% |
Anti-CCR4 trial |
| 70sM |
Stage IVA, T4NXM0B2 |
CD4:CD8 of 132.9, discrete subset of CD3+/CD4+/CD26- of 96% (33251 cells/μl) |
9.17% |
In vivo Romidepsin |
| 50sM |
Stage IVA, T4NXM0B2 |
CD4:CD8 of 30, discrete subset of CD3+/CD4+/CD26- of 91 % (7012 cells/μl) |
Unknown High IL-31 mRNA expression by PCR |
In vivo Romidepsin |
